VCEL: Vericel Corporation Stock

by  •  • Comments Off on VCEL: Vericel Corporation Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 1,991.90
Enterprise Value ($M) 1,917.38
Book Value ($M) 291.97
Book Value / Share 5.82
Price / Book 6.82
NCAV ($M) 72.02
NCAV / Share 1.44
Price / NCAV 27.66

Profitability (mra)
Return on Invested Capital (ROIC) 0.03
Return on Assets (ROA) 0.03
Return on Equity (ROE) 0.04

Liquidity (mrq)
Quick Ratio 3.89
Current Ratio 4.23

Balance Sheet (mrq) ($M)
Current Assets 212.78
Assets 432.72
Liabilities 140.75
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 237.22
Operating Income 4.52
Net Income 10.36
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 58.16
Cash from Investing -79.03
Cash from Financing 19.05

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Brown Capital Management Llc 6.56 -15.43
11-14 13G/A Rtw Investments, Lp 0.00 -100.00
10-18 13G/A State Street Corp 5.00 -8.83

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: September 30, 2024 ☐ TRANSITION REPORT PURSUAN
2024-08-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED: March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-28 69,148 369,967 18.69
2025-04-25 125,200 381,940 32.78
2025-04-24 96,613 349,394 27.65
2025-04-23 81,062 371,067 21.85

(click for more detail)

Similar Companies
TRVI – Trevi Therapeutics, Inc. TVTX – Travere Therapeutics, Inc.
URGN – UroGen Pharma Ltd. VERA – Vera Therapeutics, Inc.
VNDA – Vanda Pharmaceuticals Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Vericel Corporation